title: Long-term molecular remission with persistence of BCR-ABL1-specific cytotoxic T cells following imatinib withdrawal in an elderly patient with Philadelphia-positive ALL.
authors.affiliation: Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Haematology Unit, AOU Policlinico, Modena, Italy.
authors.forename: Giovanni
authors.initials: G
authors.lastname: Riva
authors.forename: Mario
authors.initials: M
authors.lastname: Luppi
authors.forename: Ivana
authors.initials: I
authors.lastname: Lagreca
authors.forename: Patrizia
authors.initials: P
authors.lastname: Barozzi
authors.forename: Chiara
authors.initials: C
authors.lastname: Quadrelli
authors.forename: Daniela
authors.initials: D
authors.lastname: Vallerini
authors.forename: Eleonora
authors.initials: E
authors.lastname: Zanetti
authors.forename: Sabrina
authors.initials: S
authors.lastname: Basso
authors.forename: Fabio
authors.initials: F
authors.lastname: Forghieri
authors.forename: Monica
authors.initials: M
authors.lastname: Morselli
authors.forename: Monica
authors.initials: M
authors.lastname: Maccaferri
authors.forename: Ambra
authors.initials: A
authors.lastname: Paolini
authors.forename: Valeria
authors.initials: V
authors.lastname: Fantuzzi
authors.forename: Andrea
authors.initials: A
authors.lastname: Messerotti
authors.forename: Rossana
authors.initials: R
authors.lastname: Maffei
authors.forename: Ilaria
authors.initials: I
authors.lastname: Iacobucci
authors.forename: Giovanni
authors.initials: G
authors.lastname: Martinelli
authors.forename: Roberto
authors.initials: R
authors.lastname: Marasca
authors.forename: Franco
authors.initials: F
authors.lastname: Narni
authors.forename: Patrizia
authors.initials: P
authors.lastname: Comoli
authors.forename: Leonardo
authors.initials: L
authors.lastname: Potenza
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001549:Benzamides / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000235:genetics* / Q000276:immunology*; D006801:Humans; D000068877:Imatinib Mesylate; D007156:Immunologic Memory; D016130:Immunophenotyping; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000235:genetics* / Q000276:immunology*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use; D012074:Remission Induction; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology* / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; C581634:BCR-ABL1 fusion protein, human; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl
keywords: ALL; BCR-ABL1; Imatinib; MRD; T cells